Leo V. Lacerna

995 total citations
13 papers, 802 citations indexed

About

Leo V. Lacerna is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Orthopedics and Sports Medicine. According to data from OpenAlex, Leo V. Lacerna has authored 13 papers receiving a total of 802 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Orthopedics and Sports Medicine. Recurrent topics in Leo V. Lacerna's work include Bone health and treatments (12 papers), Estrogen and related hormone effects (4 papers) and Cancer Diagnosis and Treatment (4 papers). Leo V. Lacerna is often cited by papers focused on Bone health and treatments (12 papers), Estrogen and related hormone effects (4 papers) and Cancer Diagnosis and Treatment (4 papers). Leo V. Lacerna collaborates with scholars based in United States, Switzerland and Australia. Leo V. Lacerna's co-authors include John Hohneker, Adam Brufsky, W G Harker, Elizabeth Tan-Chiu, Robert R. Carroll, C. W. Seidler, J. Thaddeus Beck, Edith A. Perez, Stephanie Petrone and Tomasz M. Beer and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Urology.

In The Last Decade

Leo V. Lacerna

13 papers receiving 777 citations

Peers

Leo V. Lacerna

ONCOL

OSM

PRM

RNMI

GENET

Narciso Hernández Toriz Mexico

Lixian Jin United States

Amy Kupic United States

W. Dornoff Germany

T. Taube Finland

Georgia Litsas United States

Richard Leff United States

Viktor Wette Austria

Yong Jiang Hei United States

Ioannis Melakopoulos Greece

Narciso Hernández Toriz Mexico

Leo V. Lacerna

596 ×0.8

ONCOL

337 ×0.9

OSM

353 ×1.4

PRM

168 ×0.8

RNMI

28 ×0.2

GENET

Citations per year, relative to Leo V. Lacerna Leo V. Lacerna (= 1×) peers Narciso Hernández Toriz

Countries citing papers authored by Leo V. Lacerna

Since Specialization

Citations

This map shows the geographic impact of Leo V. Lacerna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leo V. Lacerna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leo V. Lacerna more than expected).

Fields of papers citing papers by Leo V. Lacerna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leo V. Lacerna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leo V. Lacerna. The network helps show where Leo V. Lacerna may publish in the future.

Co-authorship network of co-authors of Leo V. Lacerna

This figure shows the co-authorship network connecting the top 25 collaborators of Leo V. Lacerna. A scholar is included among the top collaborators of Leo V. Lacerna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leo V. Lacerna. Leo V. Lacerna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Weitzman, Richard E., Nicholas Sauter, Erik Fink Eriksen, et al.. (2007). Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006. Critical Reviews in Oncology/Hematology. 62(2). 148–152. 146 indexed citations

Israeli, Ron, Steven Rosenberg, Daniel R. Saltzstein, et al.. (2007). The Effect of Zoledronic Acid on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy. Clinical Genitourinary Cancer. 5(4). 271–277. 95 indexed citations

Brufsky, Adam, Steven W. Papish, Patrick Cobb, et al.. (2007). P154 Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). The Breast. 16. S57–S57. 20 indexed citations

Nordstrom, Beth, Christiane Langer, A. Hussain, et al.. (2007). Renal function among cancer patients with bone metastases treated with zoledronic acid in a real world setting. Journal of Clinical Oncology. 25(18_suppl). 19540–19540. 1 indexed citations

Brufsky, Adam, Nigel Bundred, RE Coleman, et al.. (2007). P153 An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). The Breast. 16. S57–S57. 13 indexed citations

Brufsky, Adam, W G Harker, J. Thaddeus Beck, et al.. (2006). Zoledronic Acid Inhibits Adjuvant Letrozole–Induced Bone Loss in Postmenopausal Women With Early Breast Cancer. Journal of Clinical Oncology. 25(7). 829–836. 236 indexed citations

Ryan, Christopher W., et al.. (2006). Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer. The Journal of Urology. 176(3). 972–978. 107 indexed citations

Brufsky, Adam, W G Harker, J. Thaddeus Beck, et al.. (2005). Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial. Journal of Clinical Oncology. 23(16_suppl). 533–533. 47 indexed citations

Polascik, Thomas J., Robert Given, Gary Karlin, et al.. (2005). Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology. 66(5). 1054–1059. 35 indexed citations

10.

Vogel, C. L., et al.. (2004). Safety of zoledronic acid in patients who have previously received bisphosphonate therapy. Journal of Clinical Oncology. 22(14_suppl). 8156–8156. 1 indexed citations

11.

Vogel, Charles L., Ronald Yanagihara, Frederick M. Schnell, et al.. (2004). Safety and Pain Palliation of Zoledronic Acid in Patients with Breast Cancer, Prostate Cancer, or Multiple Myeloma Who Previously Received Bisphosphonate Therapy. The Oncologist. 9(6). 687–695. 63 indexed citations

12.

Lacerna, Leo V.. (2003). Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. Seminars in Oncology. 30(5 Suppl 16). 150–160. 37 indexed citations

13.

Lacerna, Leo V., William Sheridan, Russell L. Basser, et al.. (2000). Stem cell factor. 31–46. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact